App-Quantinova.ai

miRNA21 as a specific marker for the detection of circulating tumor cell.

Jose Manuel Ordonez - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

N/A

Molecular profiling of circulating tumor cells in non-metastatic breast cancer.

Victoria Forte - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Non-invasive and repeatable EGFR analysis using novel enrichment method for circulating tumor cells.

Dong-Hyoung Lee - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Prospective characterization of circulating tumor cells (CTCs) in head and neck cancer patients receiving definitive radiotherapy.

Michael Joseph Eblan - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

N/A

Subclassification of prostate cancer circulating tumor cells (CTCs) by nuclear size reveals very-small nuclear CTCs in patients with visceral metastases.

Yi-Tsung Lu - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs).

Amelie Schramm - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

The GILUPI CellCollector as an in vivo tool for circulating tumor cell enumeration and molecular characterization in lung cancer patients.

Klaus Luecke - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

A prospective evaluation of cell free DNA (cfDNA) genotyping and circulating tumor cells (CTC) in EGFR mutant NSCLC patients (pts) treated with erlotinib.

Masahiko Yanagita - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Erlotinib hydrochloride

Trastuzumab in HER2-negative early breast cancer as adjuvant treatment for circulating tumor cells (CTCs) (Treat CTC)

Ignatiadis M - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

The DETECT-study concept: Treatment based on the phenotype of circulating tumor cells in HER2-negative metastatic breast cancer

Jaeger BAS - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fluorescein sodium

HIOB trial - Hypofractionated whole-breast irradiation preceded by intraoperative radiotherapy with electrons as anticipated boost

Reitsamer R - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

carisoprodol

Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients

Bidard F-C - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

TP53

Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01)

de Groot S - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Etirinotecan pegol target-specific pharmacodynamic biomarkers in circulating tumor cells from patients with metastatic breast cancer in the phase 3 BEACON study

Perez EA - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

etirinotecan pegol

Fulvestrant alone versus fulvestrant and everolimus versus fulvestrant, everolimus and anastrozole: A Phase III randomized, placebo-controlled trial in postmenopausal patients with hormone-receptor-positive stage IV breast cancer: SWOG-Clinical Trials Initiative (CTI)* S1222

Somlo G - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Anastrozole

Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial

Liu MC - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Prospective characterization of HER2-positive circulating tumor cells in patients with HER2-negative metastatic breast cancer

Krop IE - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Prognostic relevance of circulating tumor cells across different molecular subgroups in the adjuvant SUCCESS-A study

Janni W - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Gemcitabine

Circulating tumor cells (CTC) are associated with defects in innate and adaptive immunity in inflammatory breast cancer (IBC) patients

Mego M - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Circulating tumor cell count as early predictor of metastatic spread in breast cancer patients with limited metastatic dissemination

Giordano A - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Breast cancer

N/A

Filters

1671 Abstracts